178 related articles for article (PubMed ID: 32841040)
21. Lipophilic activated ester prodrug approach for drug delivery to the intestinal lymphatic system.
Lee JB; Zgair A; Malec J; Kim TH; Kim MG; Ali J; Qin C; Feng W; Chiang M; Gao X; Voronin G; Garces AE; Lau CL; Chan TH; Hume A; McIntosh TM; Soukarieh F; Al-Hayali M; Cipolla E; Collins HM; Heery DM; Shin BS; Yoo SD; Kagan L; Stocks MJ; Bradshaw TD; Fischer PM; Gershkovich P
J Control Release; 2018 Sep; 286():10-19. PubMed ID: 30016732
[TBL] [Abstract][Full Text] [Related]
22. Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles.
Zhou T; Su H; Dash P; Lin Z; Dyavar Shetty BL; Kocher T; Szlachetka A; Lamberty B; Fox HS; Poluektova L; Gorantla S; McMillan J; Gautam N; Mosley RL; Alnouti Y; Edagwa B; Gendelman HE
Biomaterials; 2018 Jan; 151():53-65. PubMed ID: 29059541
[TBL] [Abstract][Full Text] [Related]
23. Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates.
Chen X; Seifert SM; Castillo-Mancilla JR; Bushman LR; Zheng JH; Kiser JJ; MaWhinney S; Anderson PL
PLoS One; 2016; 11(11):e0165505. PubMed ID: 27832147
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection.
Wang LH; Begley J; St Claire RL; Harris J; Wakeford C; Rousseau FS
AIDS Res Hum Retroviruses; 2004 Nov; 20(11):1173-82. PubMed ID: 15588339
[TBL] [Abstract][Full Text] [Related]
25. Transgender women on oral HIV pre-exposure prophylaxis have significantly lower tenofovir and emtricitabine concentrations when also taking oestrogen when compared to cisgender men.
Shieh E; Marzinke MA; Fuchs EJ; Hamlin A; Bakshi R; Aung W; Breakey J; Poteat T; Brown T; Bumpus NN; Hendrix CW
J Int AIDS Soc; 2019 Nov; 22(11):e25405. PubMed ID: 31692269
[TBL] [Abstract][Full Text] [Related]
26. 3D printed, controlled release, tritherapeutic tablet matrix for advanced anti-HIV-1 drug delivery.
Siyawamwaya M; du Toit LC; Kumar P; Choonara YE; Kondiah PPPD; Pillay V
Eur J Pharm Biopharm; 2019 May; 138():99-110. PubMed ID: 29655904
[TBL] [Abstract][Full Text] [Related]
27. Role of carbohydrate receptors in the macrophage uptake of dextran-coated iron oxide nanoparticles.
Chao Y; Karmali PP; Simberg D
Adv Exp Med Biol; 2012; 733():115-23. PubMed ID: 22101717
[TBL] [Abstract][Full Text] [Related]
28. Homing of negatively charged albumins to the lymphatic system: general implications for drug targeting to peripheral tissues and viral reservoirs.
Swart PJ; Beljaars L; Kuipers ME; Smit C; Nieuwenhuis P; Meijer DK
Biochem Pharmacol; 1999 Nov; 58(9):1425-35. PubMed ID: 10513986
[TBL] [Abstract][Full Text] [Related]
29. Mechanistic Study on the Use of the l-Type Amino Acid Transporter 1 for Brain Intracellular Delivery of Ketoprofen via Prodrug: A Novel Approach Supporting the Development of Prodrugs for Intracellular Targets.
Puris E; Gynther M; de Lange ECM; Auriola S; Hammarlund-Udenaes M; Huttunen KM; Loryan I
Mol Pharm; 2019 Jul; 16(7):3261-3274. PubMed ID: 31180686
[TBL] [Abstract][Full Text] [Related]
30. Dose response for starting and stopping HIV preexposure prophylaxis for men who have sex with men.
Seifert SM; Glidden DV; Meditz AL; Castillo-Mancilla JR; Gardner EM; Predhomme JA; Rower C; Klein B; Kerr BJ; Guida LA; Zheng JH; Bushman LR; Anderson PL
Clin Infect Dis; 2015 Mar; 60(5):804-10. PubMed ID: 25409469
[TBL] [Abstract][Full Text] [Related]
31. Tenofovir diphosphate and emtricitabine triphosphate concentrations in blood cells compared with isolated peripheral blood mononuclear cells: a new measure of antiretroviral adherence?
Adams JL; Sykes C; Menezes P; Prince HM; Patterson KB; Fransen K; Crucitti T; De Baetselier I; Van Damme L; Kashuba AD
J Acquir Immune Defic Syndr; 2013 Mar; 62(3):260-6. PubMed ID: 23111578
[TBL] [Abstract][Full Text] [Related]
32. Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066).
Hendrix CW; Andrade A; Bumpus NN; Kashuba AD; Marzinke MA; Moore A; Anderson PL; Bushman LR; Fuchs EJ; Wiggins I; Radebaugh C; Prince HA; Bakshi RP; Wang R; Richardson P; Shieh E; McKinstry L; Li X; Donnell D; Elharrar V; Mayer KH; Patterson KB
AIDS Res Hum Retroviruses; 2016 Jan; 32(1):32-43. PubMed ID: 26414912
[TBL] [Abstract][Full Text] [Related]
33. Lymphatic targeting of anti-HIV nucleosides: distribution of 2',3'-dideoxyinosine after intravenous and oral administration of dipalmitoylphosphatidyl prodrug in mice.
Manouilov KK; Xu ZS; Boudinot FD; Schinazi RF; Chu CK
Antiviral Res; 1997 May; 34(3):91-9. PubMed ID: 9191016
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetic testing of a first-generation cabotegravir prodrug in rhesus macaques.
McMillan J; Szlachetka A; Zhou T; Morsey B; Lamberty B; Callen S; Gautam N; Alnouti Y; Edagwa B; Gendelman HE; Fox HS
AIDS; 2019 Mar; 33(3):585-588. PubMed ID: 30289818
[TBL] [Abstract][Full Text] [Related]
35. Impact of pharmacogenetics and pregnancy on tenofovir and emtricitabine pharmacokinetics.
Gini J; Olagunju A; Dickinson L; Waitt C; Neary M; Else LJ; Siccardi M; Khoo S
Pharmacogenomics; 2019 Mar; 20(4):217-223. PubMed ID: 30767719
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study.
Dumond JB; Adams JL; Prince HM; Kendrick RL; Wang R; Jennings SH; Malone S; White N; Sykes C; Corbett AH; Patterson KB; Forrest A; Kashuba AD
HIV Med; 2013 Aug; 14(7):401-9. PubMed ID: 23433482
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of emtricitabine, didanosine and efavirenz administered once-daily for the treatment of HIV-infected adults (pharmacokinetic substudy of the ANRS 091 trial).
Molina JM; Peytavin G; Perusat S; Lascoux-Combes C; Sereni D; Rozenbaum W; Chene G
HIV Med; 2004 Mar; 5(2):99-104. PubMed ID: 15012649
[TBL] [Abstract][Full Text] [Related]
38. Emtricitabine prodrugs with improved anti-HIV activity and cellular uptake.
Agarwal HK; Chhikara BS; Bhavaraju S; Mandal D; Doncel GF; Parang K
Mol Pharm; 2013 Feb; 10(2):467-76. PubMed ID: 22917277
[TBL] [Abstract][Full Text] [Related]
39. Plasma Tenofovir, Emtricitabine, and Rilpivirine and Intracellular Tenofovir Diphosphate and Emtricitabine Triphosphate Pharmacokinetics following Drug Intake Cessation.
Dickinson L; Yapa HM; Jackson A; Moyle G; Else L; Amara A; Khoo S; Back D; Karolia Z; Higgs C; Boffito M
Antimicrob Agents Chemother; 2015 Oct; 59(10):6080-6. PubMed ID: 26195515
[TBL] [Abstract][Full Text] [Related]
40. Formulation optimization of an ephrin A2 targeted immunoliposome encapsulating reversibly modified taxane prodrugs.
Huang ZR; Tipparaju SK; Kirpotin DB; Pien C; Kornaga T; Noble CO; Koshkaryev A; Tran J; Kamoun WS; Drummond DC
J Control Release; 2019 Sep; 310():47-57. PubMed ID: 31400383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
